CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel cancer treatment using Marker-Agnostic Tumor-Anchoring Chimera (MATRAC) technology, which targets the acidic environment of tumors for delivering immune-modulating therapies. The goal is to enhance the effectiveness and safety of cancer immunotherapy.
Cancer immunotherapy represents a groundbreaking advancement in oncology, leveraging the immune system to combat malignancies with enhanced specificity and reduced systemic toxicity compared to traditional therapies.
However, despite significant progress, current immunotherapies face limitations, particularly in targCancer immunotherapy represents a groundbreaking advancement in oncology, leveraging the immune system to combat malignancies with enhanced specificity and reduced systemic toxicity…
UNIVERSITEIT GENT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
